Zhao Ying, Kang Fuli, Kong Xiangshu, Wang Ning
Department of Gynecology and Obstetrics, Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Front Immunol. 2025 May 22;16:1569011. doi: 10.3389/fimmu.2025.1569011. eCollection 2025.
Small cell neuroendocrine carcinoma of the ovary is rare pathological type with an undefined mechanism, low incidence, but high metastatic rate, high aggressiveness, and very poor prognosis, and there are no standardized treatment protocols or guidelines. In this article, we report a 48-year-old woman diagnosed with small cell neuroendocrine carcinoma of the ovary after puncture biopsy of a pelvic mass, who underwent 8 cycles of paclitaxel+carboplatin regimen chemotherapy (with the addition of the anti-angiogenesis targeted agent bevacizumab in the first 2 times, and the immunosuppressant tirilizumab in the last 2 times), followed by 12 times of tirilizumab monotherapy maintenance therapy, which was highly effective. It is believed that with newer technologies, the use of surgery, chemotherapy combined with immunotherapy, targeted therapy, genetic testing and construction of animal tumor models will play a key role in the treatment and monitoring of the prognosis of this rare disease.
卵巢小细胞神经内分泌癌是一种罕见的病理类型，发病机制不明，发病率低，但转移率高、侵袭性强、预后极差，且尚无标准化的治疗方案或指南。在本文中，我们报告了一名48岁女性，经盆腔肿物穿刺活检确诊为卵巢小细胞神经内分泌癌，该患者接受了8个周期的紫杉醇+卡铂方案化疗（前2次加用抗血管生成靶向药物贝伐珠单抗，后2次加用免疫抑制剂替雷利珠单抗），随后接受了12次替雷利珠单抗单药维持治疗，效果显著。相信随着新技术的出现，手术、化疗联合免疫治疗、靶向治疗、基因检测以及动物肿瘤模型的构建在这种罕见疾病的治疗和预后监测中将发挥关键作用。
